AADI Bioscience AADI Bioscience AADI Bioscience
Navigation
  • Company
    • The Company
    • Leadership
    • Board of Directors
  • Our Science
    • mTOR Pathway
    • TSC1 &TSC2
    • nab Technology Platform
    • Publications and Abstracts
  • Our Medicine
    • Our Medicine
    • Advanced Malignant PEComa
    • Expanded Access
  • Pipeline
  • Patients
    • Overview
    • Patient Advocacy
    • Clinical Trials
  • Investors & News
    • IR Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • Press Releases
    • Event Calendar
    • Presentations
      • Corporate Presentations
      • Scientific Presentations
    • Financial
      • SEC Filings
      • Financial Reports
      • Quarterly Results
      • Forms
    • Governance
      • Governance Highlights
      • Committee Composition
    • IR Resources
      • Investor FAQ
      • Information Request
      • Email Alerts
      • IR Contacts
  • Contact Us
    • General Contact
    • For Healthcare Professionals
    • Careers

Gallery in Lightbox

Home Featured Gallery in Lightbox
Jul
22

Gallery in Lightbox

admin   No comments yet

Related Portfolios

Audio Player
shadow
Blik
shadow
TULKOU
shadow
Fullwidth Portfolio Post
shadow
Battle Lines
shadow
Fortune Elephant Dream
shadow
Social Media
shadow
Messaging Application
shadow
Left Sidebar Portfolio Post
shadow
Gallery
Thumbnail Gallery
shadow
Synchronizing Application
shadow
HTML5 Video Post
shadow

Recent Articles

  • Biomarker Analysis From AMPECT Correlating Response to nab-Sirolimus in PEComa With TSC1 and TSC2 Inactivating Alterations
  • Synergistic Antitumor Activity of nab-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
  • Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
  • Mohammad Hirmand, MD
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

17383 Sunset Blvd, Suite A250
Pacific Palisades, CA 90272

  • Home
  • Leadership
  • Pipeline
  • Patients
  • Contact
  • Careers
  • Terms & Conditions
  • Privacy